Literature DB >> 16496015

Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype.

T Watanabe1, M Sudoh, M Miyagishi, H Akashi, M Arai, K Inoue, K Taira, M Yoshiba, M Kohara.   

Abstract

RNA interference (RNAi) can be used to inhibit viral replication in mammalian cells and therefore could be a powerful new antiviral therapy. Small interfering RNA (siRNA) may be effective for RNAi, but there are some technical problems that must be solved in each case, for example, predicting the effective siRNA target site and targeting heterogeneous sequences in a virus population. We show here that diced siRNA generated from long double-stranded RNA (dsRNA) is highly effective for inducing RNAi in HuH-7 cells harboring hepatitis C virus (HCV) replicons and can overcome variations in the HCV genotype. However, in mammalian cells, long dsRNA induced an interferon response and caused cell death. Here we describe an improvement of this method, U6 promoter-driven expression of long hairpin-RNA with multiple point mutations in the sense strand. This can efficiently silence HCV RNA replication and HCV protein expression without triggering the interferon response or cell death normally caused by dsRNA. In conclusion, intracellular-diced dsRNA efficiently induces RNAi, and, despite the high rate of mutation in HCV, it should be a feasible therapeutic strategy for silencing HCV RNA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16496015     DOI: 10.1038/sj.gt.3302734

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  34 in total

1.  All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution.

Authors:  Dirk Grimm
Journal:  Mol Ther       Date:  2012-09       Impact factor: 11.454

2.  Long double-stranded multiplex siRNAs for dual genes silencing.

Authors:  Wei Peng; Jianxin Chen; Yinchao Qin; Zhenjun Yang; York Yuanyuan Zhu
Journal:  Nucleic Acid Ther       Date:  2013-05-08       Impact factor: 5.486

3.  Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect.

Authors:  Tatsuo Kanda; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

4.  Deriving four functional anti-HIV siRNAs from a single Pol III-generated transcript comprising two adjacent long hairpin RNA precursors.

Authors:  Sheena Saayman; Patrick Arbuthnot; Marc S Weinberg
Journal:  Nucleic Acids Res       Date:  2010-06-04       Impact factor: 16.971

Review 5.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

6.  Hepatitis C virus impairs p53 via persistent overexpression of 3beta-hydroxysterol Delta24-reductase.

Authors:  Tomohiro Nishimura; Michinori Kohara; Kosuke Izumi; Yuri Kasama; Yuichi Hirata; Ying Huang; Masahiro Shuda; Chise Mukaidani; Takashi Takano; Yuko Tokunaga; Hideko Nuriya; Masaaki Satoh; Makoto Saito; Chieko Kai; Kyoko Tsukiyama-Kohara
Journal:  J Biol Chem       Date:  2009-10-27       Impact factor: 5.157

7.  Optimization of linear double-stranded RNA for the production of multiple siRNAs targeting hepatitis C virus.

Authors:  Duckhyang Shin; Hyeon Lee; Soo In Kim; Yeup Yoon; Meehyein Kim
Journal:  RNA       Date:  2009-03-26       Impact factor: 4.942

Review 8.  Lentiviral delivery of short hairpin RNAs.

Authors:  N Manjunath; Haoquan Wu; Sandesh Subramanya; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2009-03-31       Impact factor: 15.470

9.  RNA polymerase III can drive polycistronic expression of functional interfering RNAs designed to resemble microRNAs.

Authors:  Lindsey L Snyder; Iqbal Ahmed; Laura F Steel
Journal:  Nucleic Acids Res       Date:  2009-08-13       Impact factor: 16.971

10.  Combinatorial RNAi against HIV-1 using extended short hairpin RNAs.

Authors:  Ying Poi Liu; Karin Jasmijn von Eije; Nick C T Schopman; Jan-Tinus Westerink; Olivier ter Brake; Joost Haasnoot; Ben Berkhout
Journal:  Mol Ther       Date:  2009-08-11       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.